Forest, Gedeon Richter compound meets bipolar endpoint

Forest Laboratories Inc. (NYSE:FRX) and partner Gedeon Richter Ltd. (Budapest:RICHTER) said cariprazine met the primary endpoint in a Phase III trial to treat acute mania associated with bipolar I dis...